Status:
UNKNOWN
Effectiveness and Safety of Mobile Artificial Cervical Vertebrae Replacement for Patients With Cervical Spondylosis
Lead Sponsor:
Xi'an International Medical Center Hospital
Collaborating Sponsors:
Second Affiliated Hospital of Xi'an Jiaotong University
Conditions:
Cervical Spondylosis
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The research team designed an artificial cervical joint prosthesis suitable for subtotal resection of the lower cervical vertebral body. Previous studies regarding cadaver and animal experiments have ...
Detailed Description
Artificial cervical disc technology has achieved certain clinical effects in the treatment of single-segment lesions of the lower cervical spine. However, simple artificial cervical disc replacement i...
Eligibility Criteria
Inclusion
- (1)Age: 18-70 years, irrespective of sex;
- (2)For mobile artificial cervical vertebrae replacement, patients with cervical spondylosis who are planned to undergo anterior cervical corpectomy and resection of two adjacent intervertebral discs;
- (3)For anterior cervical corpectomy and fusion, patients with cervical spondylosis who are planned to undergo anterior cervical corpectomy and resection of two adjacent intervertebral discs;
Exclusion
- (1) Patients who have participated in other clinical studies 3 months before the inception of the study;
- (2) Abnormalities in liver and kidney functions (aspartate aminotransferase, alanine aminotransferase, blood creatinine and urea nitrogen levels are 1.5 times higher than normal);
- (3) Obvious abnormalities in the blood system;
- (4) Abuse of drugs or ethanol;
- (5) Patients who have brain disorders, abnormal judging ability, or cannot cooperate with the observer;
- (6) Coronary heart disease or severe kidney disease;
- (7) Severe metabolic diseases and endocrine diseases that are out of drug control;
- (8) Pregnant and lactating women and couples who are about to become pregnant in the near future;
- (9) Severe lung diseases such as asthma and lung dysfunction;
- (10) Immunodeficiency;
- (11) Single-segment intervertebral disc herniation or compression;
- (12) 3 or more vertebral segments herniated or spinal cord compression due to ligament ossification;
- (13) Active infection (systemic or local cervical spine) or a history of local cervical spine infection;
- (14) A history of anterior cervical surgery;
- (15) Patients with a need for posterior surgical treatments, with severe arthritis of the cervical spine joint process, and with spinal cord compression on the back;
- (16) Severe osteoporosis;
- (17) Cervical vertebra deformity;
- (18) A history of ossification of the posterior longitudinal ligament of the cervical spine, ankylosing spondylitis, and heterotopic ossification;
- (19) Severe cervical spine instability or trauma to the posterior structure of the cervical spine, and cervical spondylolisthesis;
- (20) Abnormal soft tissues anterior to the cervical spine (tracheal or esophageal malformations, and a history of radiotherapy), and obesity;
- (21) Allergy to prosthetic materials;
- (22) Patients who have tumors that cannot be completely resected and patients who are predicted to suffer prosthetic loosening during survival time;
- (23) Other contraindications for surgery.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04813211
Start Date
June 1 2021
End Date
November 1 2022
Last Update
April 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xi'an International Medical Center Hospital
Xi'an, Shaanxi, China, 710100